Defilade Capital Management, L.P. is an SEC-registered investment adviser based in Emeryville, CA that reports managing 1 hedge fund on Form ADV. It reports $1.5 billion in regulatory assets under management. Its private funds, of all types, hold $1.5 billion in gross assets. Its disclosed U.S. stock holdings returned an estimated +3.1% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +3.1% from Q1 2026 to Q2 2026, compared with +9.5% for the S&P 500, based on 13F filings.
- Regulatory assets under management
- $1.5 billionForm ADV Item 5.F
- Gross assets of private funds
- $1.5 billionAll private fund types, Form ADV
- Hedge funds managed
- 11 private funds in total
- Employees
- 7Form ADV Item 5.A
- Registration
- SEC-registered adviserCRD 337997
- Latest Form ADV
- 06/26/2026Disciplinary disclosures: none reported
Estimated 13F portfolio performance
Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.
| Quarter | Est. 13F return | S&P 500 |
|---|---|---|
| Q2 2026 | +8.1% | +14.8% |
| Q1 2026 | -4.7% | -4.6% |
Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures
Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.
13F holdings as of Sep 30, 2026
All 30 share positions ($598,799,890) reported by Defilade Capital Management, L.P. on Form 13F for the quarter ended Sep 30, 2026, filed Nov 16, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.
Share of the reported 13F portfolio, ten largest positions
- Pfizer Inc7.26%
- Eli Lilly & Co6.72%
- Biomarin Pharmaceutical Inc6.03%
- Gilead Sciences Inc5.64%
- Axsome Therapeutics Inc.5.40%
- Amgen Inc5.21%
- Oric Pharmaceuticals Inc5.11%
- Ascendis Pharma A/s4.90%
- Intuitive Surgical Inc4.88%
- Stryker Corporation3.75%
| Stock | Value | % of 13F portfolio | Shares | Shares vs prior quarter |
|---|---|---|---|---|
| Pfizer Inc | $43,492,971 | 7.26% | 1,524,999 | -13.93% |
| Eli Lilly & Co | $40,236,300 | 6.72% | 34,774 | -11.03% |
| Biomarin Pharmaceutical Inc | $36,115,320 | 6.03% | 601,922 | -11.74% |
| Gilead Sciences Inc | $33,770,557 | 5.64% | 226,572 | New |
| Axsome Therapeutics Inc. | $32,336,659 | 5.40% | 175,371 | New |
| Amgen Inc | $31,225,039 | 5.21% | 74,079 | New |
| Oric Pharmaceuticals Inc | $30,610,535 | 5.11% | 2,272,497 | +116.91% |
| Ascendis Pharma A/s | $29,357,718 | 4.90% | 128,858 | +35.86% |
| Intuitive Surgical Inc | $29,220,432 | 4.88% | 71,860 | New |
| Stryker Corporation | $22,450,894 | 3.75% | 81,524 | New |
| Vera Therapeutics Inc | $21,065,253 | 3.52% | 652,377 | New |
| Cogent Biosciences Inc | $20,225,273 | 3.38% | 631,645 | +60.54% |
| Veeva SYS Inc | $19,736,298 | 3.30% | 69,141 | -70.79% |
| Royalty Pharma PLC | $19,387,192 | 3.24% | 332,200 | New |
| Agios Pharmaceuticals Inc | $18,963,074 | 3.17% | 570,318 | +4.29% |
| Thermo Fisher Scientific Inc | $17,867,898 | 2.98% | 26,469 | -49.03% |
| Ocular Therapeutix Inc | $17,453,177 | 2.91% | 2,275,512 | +52.69% |
| Larimar Therapeutics Inc | $15,765,533 | 2.63% | 4,934,439 | +34.45% |
| Boston Scientific Corp | $15,311,460 | 2.56% | 350,778 | New |
| Revolution Medicines Inc | $14,611,638 | 2.44% | 71,186 | -14.05% |
| Solventum Corp | $14,604,075 | 2.44% | 165,673 | -47.65% |
| Envista Holdings Corporation | $12,543,072 | 2.09% | 534,430 | -26.40% |
| Olema Pharmaceuticals Inc | $12,442,956 | 2.08% | 1,440,157 | +55.73% |
| Evommune Inc | $11,816,533 | 1.97% | 1,430,573 | +80.37% |
| Eledon Pharmaceuticals Inc | $8,919,105 | 1.49% | 3,525,338 | Unchanged |
| Icu Med Inc | $8,737,362 | 1.46% | 54,435 | -48.50% |
| Enovis Corporation | $7,301,624 | 1.22% | 399,651 | -24.87% |
| Pacs Group Inc | $6,855,085 | 1.14% | 164,984 | -23.50% |
| Black Diamond Therapeutics I | $3,338,237 | 0.56% | 1,770,948 | +5.73% |
| Mereo Biopharma Group PLC | $3,038,620 | 0.51% | 7,558,756 | Unchanged |
Changes since Jun 30, 2026
Comparing the share counts in the two quarter-end filings: 8 new positions, 17 sold out, 9 increased, 11 reduced and 2 unchanged.
Number of positions (a count, not dollars)
- New positions8
- Increased9
- Unchanged2
- Reduced11
- Sold out17
New positions
| Stock | Value | Shares |
|---|---|---|
| Gilead Sciences Inc | $33,770,557 | 226,572 |
| Axsome Therapeutics Inc. | $32,336,659 | 175,371 |
| Amgen Inc | $31,225,039 | 74,079 |
| Intuitive Surgical Inc | $29,220,432 | 71,860 |
| Stryker Corporation | $22,450,894 | 81,524 |
| Vera Therapeutics Inc | $21,065,253 | 652,377 |
| Royalty Pharma PLC | $19,387,192 | 332,200 |
| Boston Scientific Corp | $15,311,460 | 350,778 |
Sold out
| Stock | Value at Jun 30, 2026 | Shares held then |
|---|---|---|
| PTC Therapeutics Inc | $35,376,827 | 433,699 |
| Baxter Intl Inc | $31,113,982 | 1,459,380 |
| Insmed Inc | $30,049,568 | 281,838 |
| Zimmer Biomet Holdings Inc | $27,327,204 | 317,426 |
| Insulet Corp | $26,937,897 | 176,932 |
| Abbott Laboratories | $25,931,496 | 285,778 |
| Medtronic PLC | $23,727,237 | 303,301 |
| Elanco Animal Health Inc | $21,265,009 | 864,080 |
| Lantheus Hldgs Inc | $14,717,522 | 132,662 |
| Tyra Biosciences Inc | $12,037,228 | 376,870 |
| Globus Med Inc | $11,032,719 | 139,637 |
| Teleflex Incorporated | $10,155,758 | 80,118 |
| Denali Therapeutics Inc | $10,078,794 | 391,866 |
| Glaukos Corp | $9,296,695 | 66,519 |
| Staar Surgical Co | $9,241,795 | 322,126 |
| Crinetics Pharmaceuticals In | $8,959,845 | 239,440 |
| Livanova PLC | $8,829,282 | 107,373 |
Largest increases
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Oric Pharmaceuticals Inc | +1,224,807 | +116.91% | $30,610,535 | 2,272,497 |
| Ascendis Pharma A/s | +34,015 | +35.86% | $29,357,718 | 128,858 |
| Cogent Biosciences Inc | +238,204 | +60.54% | $20,225,273 | 631,645 |
| Ocular Therapeutix Inc | +785,226 | +52.69% | $17,453,177 | 2,275,512 |
| Evommune Inc | +637,428 | +80.37% | $11,816,533 | 1,430,573 |
| Olema Pharmaceuticals Inc | +515,399 | +55.73% | $12,442,956 | 1,440,157 |
| Larimar Therapeutics Inc | +1,264,304 | +34.45% | $15,765,533 | 4,934,439 |
| Agios Pharmaceuticals Inc | +23,470 | +4.29% | $18,963,074 | 570,318 |
| Black Diamond Therapeutics I | +95,949 | +5.73% | $3,338,237 | 1,770,948 |
Largest reductions
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Veeva SYS Inc | -167,568 | -70.79% | $19,736,298 | 69,141 |
| Thermo Fisher Scientific Inc | -25,465 | -49.03% | $17,867,898 | 26,469 |
| Solventum Corp | -150,781 | -47.65% | $14,604,075 | 165,673 |
| Icu Med Inc | -51,265 | -48.50% | $8,737,362 | 54,435 |
| Pfizer Inc | -246,744 | -13.93% | $43,492,971 | 1,524,999 |
| Eli Lilly & Co | -4,312 | -11.03% | $40,236,300 | 34,774 |
| Biomarin Pharmaceutical Inc | -80,083 | -11.74% | $36,115,320 | 601,922 |
| Envista Holdings Corporation | -191,678 | -26.40% | $12,543,072 | 534,430 |
| Enovis Corporation | -132,294 | -24.87% | $7,301,624 | 399,651 |
| Revolution Medicines Inc | -11,641 | -14.05% | $14,611,638 | 71,186 |
| Pacs Group Inc | -50,691 | -23.50% | $6,855,085 | 164,984 |
Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.
From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures
Hedge funds filing Form D (2)
Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.
From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures